Precision Medicine News and Research

RSS

Luminex's xMAP Biothreat Toxin Panel now available for detecting dangerous biotoxins

Quickly detecting and identifying dangerous biotoxins is now a reality, thanks to the xMAP Biothreat Toxin Panel (BTP) by Luminex. The xMAP Biothreat Toxin Panel is the first multiplex assay to rapidly detect and identify the six most easily acquired and most dangerous biotoxins. All six of these biotoxins are on the US government's list of most dangerous substances.

From Luminex 21 Jan 2015

UChicago researchers awarded NIH grants to develop novel medications for sleep apnea, asthma

Two research teams based at the University of Chicago have received prestigious grants from the National Institutes of Health to develop novel medications to treat sleep apnea and asthma.

21 Jan 2015

ASCO announces cancer Advance of the Year

The American Society of Clinical Oncology for the first time announced its cancer Advance of the Year: the transformation of treatment for the most common form of adult leukemia. Until now, many patients with chronic lymphocytic leukemia (CLL) have had few effective treatment options. Four newly approved therapies, however, are poised to dramatically improve the outlook for patients with the disease.

20 Jan 2015

Caris Life Sciences launches Caris Centers of Excellence for Precision Medicine Network

Caris Life Sciences, a leading biosciences company focused on fulfilling the promise of precision medicine, today announced the establishment of the Caris Centers of Excellence for Precision Medicine Network, and appointed John L. Marshall, M.D., as Chairman of the Network.

20 Jan 2015

Physicians in subspecialties report increased satisfaction with concierge medicine model

Attracted to the opportunity to provide concierge medicine's hallmark model of personalized care, physicians in subspecialties such as cardiology, endocrinology, pulmonology, and others are increasingly converting their practices, and reporting increased professional and personal satisfaction, according to Michael Friedlander, Principal at national healthcare consulting firm Specialdocs.

20 Jan 2015

Major investment boosts Scotland's gene research

A major investment in gene sequencing technology will secure Scotland's place as a world leader in a genomics revolution that is set to transform healthcare.

14 Jan 2015

Study: Race and ethnicity may affect breast cancer diagnoses, survival

Among nearly 375,000 U.S. women diagnosed with invasive breast cancer, the likelihood of diagnosis at an early stage, and survival after stage I diagnosis, varied by race and ethnicity, with much of the difference accounted for by biological differences, according to a study in the January 13 issue of JAMA.

14 Jan 2015

Research findings may lead to new treatment for hypothyroidism

An international research team led by physician-scientists at Rush University Medical Center have gained new insights into hypothyroidism - a condition affecting about 10 million people in the U.S. - that may lead to new treatment protocols for the disease, particularly among the approximately 15 percent of patients for whom standard treatments are less effective.

14 Jan 2015

Duke researchers grow contracting human skeletal muscle in lab

In a laboratory first, Duke researchers have grown human skeletal muscle that contracts and responds just like native tissue to external stimuli such as electrical pulses, biochemical signals and pharmaceuticals.

13 Jan 2015

Biogen Idec, Columbia University Medical Center form $30 million genomics research alliance

Biogen Idec and Columbia University Medical Center have formed a $30 million strategic alliance to conduct genetics discovery research on the underlying causes of disease and to identify new treatment approaches. As part of this agreement, a sequencing and analysis facility and shared postdoctoral program will be established at Columbia to support collaborative genetics studies.

11 Jan 2015

DiaCarta raises $8 million in Series A financing from BVCF

DiaCarta, Inc., a privately-held biotechnology company raised $8 million in Series A financing from BVCF (BioVeda China Fund). Proceeds from Series A financing will be used to expand the product portfolio and support global commercialization. Dr. Weixin Xu of BVCF will join DiaCarta board of directors.

9 Jan 2015

Proteomics market expected to experience continual growth

The market for microarrays used to study the workings of proteins are in great demand, according to Kalorama Information. The healthcare market research publisher said "proteomics" instruments, reagents and testing are needed to discover new biomarkers and even new drugs, and that the market for them topped 5 billion dollars in 2013.

8 Jan 2015

New opportunity for developing simple test to measure E2F4 activity in ER+ breast cancer patients

By looking at the expression levels of downstream genes of the regulators in breast cancer, investigators at Dartmouth Hitchcock's Norris Cotton Cancer Center, led by Chao Cheng, PhD, have identified a gene signature in E2F4 that is predictive of estrogen receptor positive (ER+) breast cancer.

8 Jan 2015

EnGeneIC closes oversubscribed Series B financing

EnGeneIC, Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, announced it has completed an oversubscribed $10 million Series B financing.

6 Jan 2015

TxCell announces further enhancement to development of Ovasave for IBD treatment

Paulsen Foundation to provide specialist management and scientific and development expertise that is dedicated to advanced therapies, i.e. cellular and gene therapies. This new class of highly promising biological therapies includes TxCell’s Ovasave.

5 Jan 2015

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

Immunotherapy, genomic profiling, and investigating game-changing drug therapies topped the list of most important cancer research and clinical developments at Dana-Farber Cancer Institute in 2014.

1 Jan 2015

InformedDNA and NIA Magellan to jointly offer evidence-based genetic benefits optimization program

InformedDNA announced today that it will collaborate with NIA Magellan, a division of Magellan Health, Inc., to offer an evidence-based genetic benefits optimization program. InformedDNA's national network of independent board-certified genetics specialists provides expert clinical review services to ensure appropriate use of genetic testing and improve patient care, while at the same time delivering significant cost savings.

30 Dec 2014

Precision Medicine News and Research

Luminex's xMAP Biothreat Toxin Panel now available for detecting dangerous biotoxins

UChicago researchers awarded NIH grants to develop novel medications for sleep apnea, asthma

ASCO announces cancer Advance of the Year

Caris Life Sciences launches Caris Centers of Excellence for Precision Medicine Network

Physicians in subspecialties report increased satisfaction with concierge medicine model

Major investment boosts Scotland's gene research

Study: Race and ethnicity may affect breast cancer diagnoses, survival

Research findings may lead to new treatment for hypothyroidism

Duke researchers grow contracting human skeletal muscle in lab

Biogen Idec, Columbia University Medical Center form $30 million genomics research alliance

DiaCarta raises $8 million in Series A financing from BVCF

Proteomics market expected to experience continual growth

New opportunity for developing simple test to measure E2F4 activity in ER+ breast cancer patients

EnGeneIC closes oversubscribed Series B financing

TxCell announces further enhancement to development of Ovasave for IBD treatment

Top cancer research and clinical developments at Dana-Farber Cancer Institute in 2014

InformedDNA and NIA Magellan to jointly offer evidence-based genetic benefits optimization program

New computational technique reveals genetic roots of autism, cancers

FDA approves Myriad’s BRACAnalysis CDx for use with ovarian cancer drug

Roche announces acquisition of Bina Technologies

Editorial Focus eBook - Peptides and Oligonucleotides (2nd edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News